ARTICLE | Clinical News

Guselkumab regulatory update

November 22, 2016 12:39 AM UTC

Johnson & Johnson’s Janssen Research & Development LLC unit submitted a BLA to FDA for guselkumab to treat moderate to severe plaque psoriasis. The submission includes data from the Phase III VOYAGE 1 trial (see BioCentury, Oct. 10). MorphoSys said it received an undisclosed milestone payment triggered by the BLA submission...

BCIQ Company Profiles

Johnson & Johnson

MorphoSys AG

BCIQ Target Profiles

Interleukin-23 (IL-23)